USPTO Examiner MERTZ PREMA MARIA - Art Unit 1646

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18740390INTERLEUKIN 18 (IL-18) VARIANTS AND FUSION PROTEINS COMPRISING SAMEJune 2024September 2024Allow301YesNo
18526598IL-15-BASED FUSIONS TO IL-12 AND IL-18December 2023February 2024Allow301YesNo
18501741DUAL CYTOKINE FUSION PROTEINS COMPRISING IL-10November 2023February 2024Allow401YesNo
18214282ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEJune 2023October 2023Allow400YesNo
18176913USE OF G-CSF ANTIBODY FOR TREATMENT OF PULMONARY FIBROSISMarch 2023May 2023Allow300YesNo
18176957SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODYMarch 2023April 2023Allow200YesNo
18168428IL-15-BASED FUSIONS TO IL-12 AND IL-18February 2023October 2023Allow802YesNo
18162368HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATIONJanuary 2023May 2023Allow300YesNo
18060816INTERLEUKIN-18 VARIANTS AND METHODS OF USEDecember 2022October 2023Allow1001YesNo
17994223ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMENovember 2022March 2023Allow400YesNo
17915808IMMUNOSTIMULATING IL-2 ANALOGSSeptember 2022May 2023Allow701YesNo
17820980IL-15-BASED FUSIONS TO IL-12 AND IL-18August 2022January 2023Allow502YesNo
17877091QTY FC FUSION RECEPTOR PROTEINSJuly 2022November 2023Allow1611YesNo
17841349ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEJune 2022August 2022Allow200YesNo
17752978HIGH CONCENTRATION ANTIBODY-CONTAINING LIQUID FORMULATIONMay 2022November 2022Allow500YesNo
17739688SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODYMay 2022February 2023Allow912YesNo
17722328TGF-Beta PolypeptidesApril 2022January 2023Allow901YesNo
17717740METHODS OF MAKING AND USING EXTRACELLULAR DOMAIN-BASED CHIMERIC PROTEINSApril 2022April 2024Allow2400YesNo
17711723ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEApril 2022June 2022Allow200YesNo
17696028METHODS OF TREATING ATOPIC DERMATITISMarch 2022February 2024Allow2311YesNo
17684460ANTI-PLASMA KALLIKREIN ANTIBODIESMarch 2022June 2024Allow2700YesNo
17684907BIOPHARMACEUTICAL COMPOSITIONSMarch 2022May 2022Allow200YesNo
17684346HV1 MODULATORS AND USESMarch 2022April 2024Allow2601YesNo
17588949Advanced Avatar Dendritic CellsJanuary 2022May 2024Allow2700YesNo
17587751ANTIBODY TO HUMAN IL-1 BETAJanuary 2022April 2024Allow2600YesNo
17585126METHODS AND COMPOSITIONS FOR NATURAL KILLER CELLSJanuary 2022April 2024Allow2701YesNo
17580038INTERLEUKIN-2 AGENTS AND USES THEREOFJanuary 2022November 2023Abandon2201YesNo
17578265ENGINEERED IL-2 Fc FUSION PROTEINSJanuary 2022March 2024Allow2601YesNo
17575438COMBINATION THERAPY FOR TREATMENT OF CORONARY ARTERY DISEASEJanuary 2022June 2024Abandon2901NoNo
17574101NK-LYSIN PEPTIDE COMPOSITIONS AND METHODS FOR THEIR USE AS ANTIMICROBIAL/ANTIVIRAL AGENTSJanuary 2022May 2022Allow401YesNo
17574479MULTI-FUNCTIONAL AND MULTI-VALENT INTERLEUKIN-TGF-BETA RECEPTOR FUSION POLYPEPTIDESJanuary 2022June 2022Allow512YesNo
17571117INTERLEUKIN-31 MONOCLONAL ANTIBODIES FOR VETERINARY USEJanuary 2022May 2024Allow2801YesNo
17561510ANTI-TGF-BETA ANTIBODIES AND THEIR USEDecember 2021March 2024Allow2701NoNo
17556208MOLECULES THAT SELECTIVELY ACTIVATE REGULATORY T CELLS FOR THE TREATMENT OF AUTOIMMUNE DISEASESDecember 2021June 2024Abandon2901NoNo
17549785HIGH CONCENTRATION FORMULATIONS OF ANTI-CSF1 AND ANTI-CSF1R ANTIBODIESDecember 2021April 2022Allow400YesNo
17530786LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOFNovember 2021February 2022Allow300YesNo
17530150TREATMENT OR PREVENTION METHOD OF RADIATION DAMAGE BY ADMINISTRATION OF IL-5 RECEPTOR ALPHA CHAIN BINDING ANTIBODYNovember 2021February 2024Allow2701YesNo
17525421HUMAN IL-23 ANTIGEN BINDING PROTEINSNovember 2021April 2024Allow2900YesNo
17523432ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOFNovember 2021September 2022Allow1012YesNo
17519069ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODIESNovember 2021February 2024Allow2701YesNo
17516082Anti-IL-6 AntibodyNovember 2021April 2024Allow2900YesNo
17451332CANCER TREATMENT BY BLOCKING HOST-INDUCED IL-1 IN COMBINATION WITH RADIOTHERAPYOctober 2021November 2023Allow2501YesNo
17504100IL-15-BASED FUSIONS TO IL-7 AND IL-21October 2021March 2024Allow2900YesNo
17492440ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEOctober 2021February 2022Allow501YesNo
17486683IL-15-BASED FUSIONS TO IL-12 AND IL-18September 2021November 2022Allow1301YesNo
17471466Compositions and Methods of Use of Alpha-1 Antitrypsin Fusion PolypeptidesSeptember 2021December 2023Allow2701YesNo
17470246SUPERAGONISTS AND ANTAGONISTS OF INTERLEUKIN-2September 2021February 2024Allow2900YesNo
17465145MULTI-LEVEL SPECIFIC TARGETING OF CANCER CELLSSeptember 2021January 2024Allow2801YesNo
17458028ANTIBODY CYTOKINE ENGRAFTED COMPOSITIONS AND METHODS OF USE FOR IMMUNOREGULATIONAugust 2021January 2024Abandon2901NoNo
17403710ANTIBODY-CYTOKINE ENGRAFTED PROTEINS AND METHODS OF USE FOR IMMUNE RELATED DISORDERSAugust 2021October 2023Allow2601YesNo
17444598COMPOSITIONS AND METHODS FOR MACROPHAGE CONVERSIONAugust 2021January 2024Allow2901YesNo
17388895THERAPEUTIC IL-13 POLYPEPTIDESJuly 2021January 2024Allow3000YesNo
17388322Anti-IL-33 Antibodies and Uses ThereofJuly 2021March 2024Allow3111YesNo
17386047IL-2 MUTEINS AND USES THEREOFJuly 2021August 2023Allow2500YesNo
17385714MULTIMERIC IL-15 SOLUBLE FUSION MOLECULES AND METHODS OF MAKING AND USING SAMEJuly 2021July 2023Allow2400YesNo
17385061IL-2 MUTEINS AND USES THEREOFJuly 2021July 2023Allow2400YesNo
17373412BIOPHARMACEUTICAL COMPOSITIONSJuly 2021November 2021Allow400YesNo
17373537BIOPHARMACEUTICAL COMPOSITIONSJuly 2021December 2021Allow500YesNo
17373223BIOPHARMACEUTICAL COMPOSITIONSJuly 2021November 2021Allow400YesNo
17363260ANTIBODIES AND POLYPEPTIDES DIRECTED AGAINST CD127June 2021October 2023Allow2801YesNo
17353987IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASESJune 2021January 2024Abandon3001NoNo
17339810MASKED CYTOKINE POLYPEPTIDESJune 2021July 2023Allow2500YesNo
17339801MASKED CYTOKINE POLYPEPTIDESJune 2021July 2023Allow2500YesNo
17333256COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASESMay 2021May 2023Allow2400YesNo
17334341METHOD FOR TREATING RHEUMATOID ARTHRITIS WITH A HUMAN IL-6 RECEPTOR ANTIBODY AND METHOTREXATEMay 2021January 2023Abandon2021NoNo
17326009Induction of IL-12 using immunotherapyMay 2021September 2023Allow2801YesNo
17320779ACTIVATABLE INTERLEUKIN-2 POLYPEPTIDES AND METHODS OF USE THEREOFMay 2021January 2024Allow3201YesNo
17314198ANTI-GM-CSF ANTIBODIESMay 2021January 2024Abandon3201NoNo
17245679ACTIVATABLE IL2 COMPOSITION AND METHODS OF USEApril 2021November 2022Allow1801YesNo
17241609Anti-IL1RAP Antibodies and Their Use for Treating HumansApril 2021June 2023Allow2500YesNo
17240260HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USEApril 2021May 2023Allow2500YesNo
17232979ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES THEREOFApril 2021October 2023Allow3001YesNo
17284693Marrow Infiltrating Lymphocytes With Increased Clonality and Uses ThereofApril 2021October 2024Abandon4201NoNo
17226506METHOD OF TREATING AUTOIMMUNE DISEASE WITH LYMPHOCYTE ANTIGEN CD5-LIKE (CD5L) PROTEINApril 2021August 2023Allow2901YesNo
17213483NK-LYSIN PEPTIDE COMPOSITIONS AND METHODS FOR THEIR USE AS ANTIMICROBIAL/ANTIVIRAL AGENTSMarch 2021October 2021Allow702YesNo
17212270Bi-Specific Fusion ProteinsMarch 2021June 2023Allow2701YesNo
17210878QTY FC FUSION RECEPTOR PROTEINSMarch 2021March 2022Allow1201YesNo
17210837QTY FC FUSION WATER SOLUBLE RECEPTOR PROTEINSMarch 2021September 2022Allow1720YesNo
17211180HETERODIMERIC PROTEINS AND USES THEREOFMarch 2021August 2023Allow2901YesNo
17208064GABA AGONISTS IN THE TREATMENT OF DISORDERS ASSOCIATED WITH METABOLIC SYNDROME AND GABA COMBINATIONS IN TREATMENT OR PROPHYLAXIS OF TYPE I DIABETESMarch 2021August 2023Allow2901YesNo
17207272INTERLEUKIN-1 INHIBITION FOR COMBINATION TREATMENT OF PANCREATIC CANCER CACHEXIAMarch 2021June 2023Allow2701YesNo
17201350IL-2 MUTEINS AND USES THEREOFMarch 2021June 2023Allow2700YesNo
17196451COMPOSITIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSEMarch 2021December 2023Abandon3310NoNo
17274460SINGLE-DOMAIN ANTIBODIES AGAINST CLL1 AND CONSTRUCTS THEREOFMarch 2021March 2024Allow3700YesNo
17172109GREMLIN-1 CRYSTAL STRUCTURE AND INHIBITORY ANTIBODYFebruary 2021June 2023Allow2901YesNo
17166441IL-7R-ALPHA BINDING COMPOUNDSFebruary 2021October 2021Allow920YesNo
17158785FUSION PROTEIN COMPRISING IL13January 2021January 2022Allow1103YesNo
17151860ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOFJanuary 2021August 2023Allow3101YesNo
17150789REGULATING IL-4 AND IL-13 LEVELS BY BLOCKING HIGH AFFINITY BINDING BY IL-3, IL-5 AND GM-CSF TO THEIR COMMON RECEPTORJanuary 2021December 2023Abandon3510NoNo
17150691IL-1Beta Neutralizing Human Monoclonal AntibodiesJanuary 2021March 2023Allow2600YesNo
17150689IL-1Beta Neutralizing Human Monoclonal AntibodiesJanuary 2021October 2023Allow3310YesNo
17144537MODIFIED IL-2 POLYPEPTIDES AND USES THEREOFJanuary 2021October 2022Allow2201YesNo
17129100Interleukin 15 Protein Complex and Use ThereofDecember 2020March 2023Allow2600YesNo
17128776METHODS AND COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS AND RELATED DISORDERSDecember 2020July 2024Abandon4210NoNo
17254054CYTOKINE-BASED BIOACTIVATABLE DRUGS AND METHODS OF USES THEREOFDecember 2020December 2022Allow2401YesNo
17124930IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOFDecember 2020August 2023Allow3201YesNo
17121375METHOD FOR IDENTIFYING ANTI-CANCER AGENTS USING AN IN VITRO CELL CULTURE SYSTEM THAT MAINTAINS CANCER CELL STEMNESSDecember 2020April 2023Allow2800YesNo
17119923IL-2 ORTHOLOGS AND METHODS OF USEDecember 2020January 2023Allow2501YesNo
17115391SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODYDecember 2020May 2023Allow3010NoNo
17109924ANTI-GM-CSF ANTIBODIES AND USES THEREOFDecember 2020November 2023Allow3500YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MERTZ, PREMA MARIA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
4
(100.0%)
Examiner Reversed
0
(0.0%)
Reversal Percentile
0.7%
Lower than average

What This Means

With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
43
Allowed After Appeal Filing
6
(14.0%)
Not Allowed After Appeal Filing
37
(86.0%)
Filing Benefit Percentile
14.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 14.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner MERTZ, PREMA MARIA - Prosecution Strategy Guide

Executive Summary

Examiner MERTZ, PREMA MARIA works in Art Unit 1646 and has examined 1,151 patent applications in our dataset. With an allowance rate of 63.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.

Allowance Patterns

Examiner MERTZ, PREMA MARIA's allowance rate of 63.5% places them in the 16% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by MERTZ, PREMA MARIA receive 1.09 office actions before reaching final disposition. This places the examiner in the 16% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by MERTZ, PREMA MARIA is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +57.9% benefit to allowance rate for applications examined by MERTZ, PREMA MARIA. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 32.0% of applications are subsequently allowed. This success rate is in the 59% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 41.1% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 81.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 54.8% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.2% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.